"Suramin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
| Descriptor ID |
D013498
|
| MeSH Number(s) |
D02.455.426.559.847.638.555.750 D02.886.645.600.080.050.650.750 D04.615.638.555.750
|
| Concept/Terms |
Suramin Sodium- Suramin Sodium
- Sodium, Suramin
- Suramin, Hexasodium Salt
- Hexasodium Salt Suramin
- Salt Suramin, Hexasodium
|
Below are MeSH descriptors whose meaning is more general than "Suramin".
Below are MeSH descriptors whose meaning is more specific than "Suramin".
This graph shows the total number of publications written about "Suramin" by people in this website by year, and whether "Suramin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Suramin" by people in Profiles.
-
Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles. Acta Biomater. 2019 01 15; 84:378-390.
-
Suramin protects from cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol. 2016 Feb 01; 310(3):F248-58.
-
BRL37344, a ?3-adrenergic receptor agonist, decreases nerve-evoked contractions in human detrusor smooth muscle isolated strips: role of BK channels. Urology. 2013 Sep; 82(3):744.e1-7.
-
Suramin decreases injury and improves regeneration of ethanol-induced steatotic partial liver grafts. J Pharmacol Exp Ther. 2013 Feb; 344(2):417-25.
-
Identification and functional characterization of the intermediate-conductance Ca(2+)-activated K(+) channel (IK-1) in biliary epithelium. Am J Physiol Gastrointest Liver Physiol. 2009 Nov; 297(5):G1009-18.
-
Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. Cancer Lett. 1996 May 15; 103(1):49-56.
-
Intravesical suramin in the prevention of transitional cell carcinoma. Urology. 1995 Jan; 45(1):59-63.
-
Postoperative complications in patients receiving suramin therapy. Surgery. 1994 Jul; 116(1):90-5.
-
Suramin inhibits growth and yet promotes insulin-like growth factor II expression in HepG2 cells. Cancer Res. 1993 Feb 01; 53(3):652-7.